Items where Author is "Derfuss, T."

2016

Kuhle, J. and Barro, C. and Andreasson, U. and Derfuss, T. and Lindberg, R. and Sandelius, A. and Liman, V. and Norgren, N. and Blennow, K. and Zetterberg, H.. (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clinical Chemistry and Laboratory Medicine, 54 (10). pp. 1655-1661.

Rasenack, M. and Derfuss, T.. (2016) Disease activity return after natalizumab cessation in multiple sclerosis. Expert Review of Neurotherapeutics, 16 (5). pp. 587-594.

Rasenack, M. and Rychen, J. and Andelova, M. and Naegelin, Y. and Stippich, C. and Kappos, L. and Lindberg, R. L. and Sprenger, T. and Derfuss, T.. (2016) Efficacy and Safety of Fingolimod in an Unselected Patient Population. PLoS One, 11 (1). e0146190.

Diebold, M. and Derfuss, T.. (2016) Immunological treatment of multiple sclerosis. Seminars in Hematology, 53 Suppl 1. pp. 54-57.

Havla, J. and Warnke, C. and Derfuss, T. and Kappos, L. and Hartung, H. P. and Hohlfeld, R.. (2016) Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Deutsches Ärzteblatt international , 113 (51-52). pp. 879-886.

Probstel, A. K. and Kuhle, J. and Lecourt, A. C. and Vock, I. and Sanderson, N. S. and Kappos, L. and Derfuss, T.. (2016) Multiple Sclerosis and Antibodies against KIR4.1. N Engl J Med, 374 (15). pp. 1496-1498.

Ziemssen, T. and Derfuss, T. and de Stefano, N. and Giovannoni, G. and Palavra, F. and Tomic, D. and Vollmer, T. and Schippling, S.. (2016) Optimizing treatment success in multiple sclerosis. Journal of Neurology, 263 (6). pp. 1053-1065.

Decard, B. F. and Derfuss, T.. (2016) Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the Future. Seminars in Neurology, 36 (2). pp. 128-139.

Derfuss, T. and Ontaneda, D. and Nicholas, J. and Meng, X. and Hawker, K.. (2016) Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. Multiple Sclerosis and Related Disorders, 8. pp. 124-130.

Kappos, L. and Arnold, D. L. and Bar-Or, A. and Camm, J. and Derfuss, T. and Kieseier, B. C. and Sprenger, T. and Greenough, K. and Ni, P. and Harada, T.. (2016) Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet Neurology, 15 (11). pp. 1148-1159.

Rust, H. and Kuhle, J. and Kappos, L. and Derfuss, T.. (2016) Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy. Neurology: Neuroimmunology & Neuroinflammation, 3 (2). e215.

Disanto, G. and Benkert, P. and Lorscheider, J. and Mueller, S. and Vehoff, J. and Zecca, C. and Ramseier, S. and Achtnichts, L. and Findling, O. and Nedeltchev, K. and Radue, E. W. and Sprenger, T. and Stippich, C. and Derfuss, T. and Louvion, J. F. and Kamm, C. P. and Mattle, H. P. and Lotter, C. and Du Pasquier, R. and Schluep, M. and Pot, C. and Lalive, P. H. and Yaldizli, O. and Gobbi, C. and Kappos, L. and Kuhle, J. and Smsc Scientific Board, . (2016) The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS One, 11 (3). e0152347.

Diebold, M. and Kappos, L. and Derfuss, T.. (2016) Zelldepletion und Myeloablation bei neuroimmunologischen Erkrankungen. Nervenarzt, 87 (8). pp. 814-820.

2015

Derfuss, T. and Curtin, F. and Guebelin, C. and Bridel, C. and Rasenack, M. and Matthey, A. and Du Pasquier, R. and Schluep, M. and Desmeules, J. and Lang, A. B. and Perron, H. and Faucard, R. and Porchet, H. and Hartung, H. P. and Kappos, L. and Lalive, P. H.. (2015) A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients. Multiple Sclerosis Journal, 21 (7). pp. 885-893.

Derfuss, T. and Curtin, F. and Guebelin, C. and Bridel, C. and Rasenack, M. and Matthey, A. and Du Pasquier, R. and Schluep, M. and Desmeules, J. and Lang, A. B. and Perron, H. and Faucard, R. and Porchet, H. and Hartung, H. P. and Kappos, L. and Lalive, P. H.. (2015) A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up. Journal of Neuroimmunology, 285. pp. 68-70.

Giovannoni, G. and de Jong, B. and Derfuss, T. and Izquierdo, G. and Mazibrada, G. and Molyneux, P. and Nicholas, R. and Overell, J. and Ziemssen, T. and Juliusson, G.. (2015) A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. Multiple Sclerosis and Related Disorders, 4 (1). pp. 83-84.

Probstel, A. K. and Sanderson, N. S. and Derfuss, T.. (2015) B Cells and Autoantibodies in Multiple Sclerosis. International Journal of Molecular Sciences , 16 (7). pp. 16576-16592.

Kuhle, J. and Disanto, G. and Dobson, R. and Adiutori, R. and Bianchi, L. and Topping, J. and Bestwick, J. P. and Meier, U. C. and Marta, M. and Dalla Costa, G. and Runia, T. and Evdoshenko, E. and Lazareva, N. and Thouvenot, E. and Iaffaldano, P. and Direnzo, V. and Khademi, M. and Piehl, F. and Comabella, M. and Sombekke, M. and Killestein, J. and Hegen, H. and Rauch, S. and D'Alfonso, S. and Alvarez-Cermeno, J. C. and Kleinova, P. and Horakova, D. and Roesler, R. and Lauda, F. and Llufriu, S. and Avsar, T. and Uygunoglu, U. and Altintas, A. and Saip, S. and Menge, T. and Rajda, C. and Bergamaschi, R. and Moll, N. and Khalil, M. and Marignier, R. and Dujmovic, I. and Larsson, H. and Malmestrom, C. and Scarpini, E. and Fenoglio, C. and Wergeland, S. and Laroni, A. and Annibali, V. and Romano, S. and Martinez, A. D. and Carra, A. and Salvetti, M. and Uccelli, A. and Torkildsen, O. and Myhr, K. M. and Galimberti, D. and Rejdak, K. and Lycke, J. and Frederiksen, J. L. and Drulovic, J. and Confavreux, C. and Brassat, D. and Enzinger, C. and Fuchs, S. and Bosca, I. and Pelletier, J. and Picard, C. and Colombo, E. and Franciotta, D. and Derfuss, T. and Lindberg, R. and Yaldizli, O. and Vecsei, L. and Kieseier, B. C. and Hartung, H. P. and Villoslada, P. and Siva, A. and Saiz, A. and Tumani, H. and Havrdova, E. and Villar, L. M. and Leone, M. and Barizzone, N. and Deisenhammer, F. and Teunissen, C. and Montalban, X. and Tintore, M. and Olsson, T. and Trojano, M. and Lehmann, S. and Castelnovo, G. and Lapin, S. and Hintzen, R. and Kappos, L. and Furlan, R. and Martinelli, V. and Comi, G. and Ramagopalan, S. V. and Giovannoni, G.. (2015) Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 21 (8). pp. 1013-1024.

Derfuss, T. and Bergvall, N. K. and Sfikas, N. and Tomic, D. L.. (2015) Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Current Medical Research and Opinion, 31 (9). pp. 1687-1691.

2013

Waschbisch, A. and Atiya, M. and Schaub, C. and Derfuss, T. and Schwab, S. and Lee, D. H. and Muller, M. and Linker, R. A.. (2013) Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity. Journal of the neurological sciences, Vol. 331, No. 1-2. pp. 72-75.

Derfuss, T. and Kuhle, J. and Lindberg, R. and Kappos, L.. (2013) Natalizumab therapy for multiple sclerosis. Seminars in neurology, Vol. 33, H. 1. pp. 26-36.

Kuhle, J. and Malmestrom, C. and Axelsson, M. and Plattner, K. and Yaldizli, O. and Derfuss, T. and Giovannoni, G. and Kappos, L. and Lycke, J.. (2013) Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta neurologica scandinavica, Vol. 128, H. 6 , e33-36.

Derfuss, T. and Kappos, L.. (2013) Predicting PML in natalizumab-treated patients: can we do better? Journal of neurology, neurosurgery, and psychiatry, Vol. 84, H. 11. pp. 1182-1183.

Preiningerova, J. L. and Baumhackl, U. and Csepany, T. and Czaplinski, A. and Deisenhammer, F. and Derfuss, T. and Fabjan, T. H. and Fazekas, F. and Fuchs, S. and Havrdova, E. and Ledinek, A. H. and Illes, Z. and Jazbec, S. S. and Klimova, E. and Komoly, S. and Kurca, E. and Linnebank, M. and Lisy, L. and Mares, J. and Prochazkova, L. and Csilla, R. and Szilasiova, J. and Stourac, P. and Talab, R. and Turcani, P. and Vachova, M. and Vecsei, L. and Vodusek, D. and Zapletalova, O. and Berger, T.. (2013) Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS). CNS neuroscience & therapeutics, Vol. 19, H. 5. pp. 302-306.

Ricklin, M. E. and Lorscheider, J. and Waschbisch, A. and Paroz, C. and Mehta, S. K. and Pierson, D. L. and Kuhle, J. and Fischer-Barnicol, B. and Sprenger, T. and Lindberg, R. L. and Kappos, L. and Derfuss, T.. (2013) T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology, Vol. 81, H. 2. pp. 174-181.

Vaney, C. and Derfuss, T.. (2013) Was gibt‘s Neues in der kausalen Behandlung der Multiplen Sklerose? Revue médicale suisse, Vol. 9, no. 371. pp. 285-287.

2012

Krumbholz, M. and Derfuss, T. and Hohlfeld, R. and Meinl, E.. (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nature reviews. Neurology, Vol. 8, H. 11. pp. 613-623.

Held, K. and Eiglmeier, I. and Himmelein, S. and Sinicina, I. and Brandt, T. and Theil, D. and Dornmair, K. and Derfuss, T.. (2012) Clonal expansions of CD8(+) T cells in latently HSV-1-infected human trigeminal ganglia. Journal of neurovirology, Vol. 18, H. 1. pp. 62-68.

Derfuss, T. and Kappos, L.. (2012) Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA, Vol. 308, H. 3. pp. 290-291.

Weier, K. and Beck, A. and Magon, S. and Amann, M. and Naegelin, Y. and Penner, I. K. and Thurling, M. and Aurich, V. and Derfuss, T. and Radue, E. W. and Stippich, C. and Kappos, L. and Timmann, D. and Sprenger, T.. (2012) Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis. Journal of neurology, Vol. 259, H. 12. pp. 2673-2680.

Derfuss, T. and Meinl, E.. (2012) Identifying autoantigens in demyelinating diseases : valuable clues to diagnosis and treatment? Current opinion in neurology, Vol. 25, H. 3. pp. 231-238.

Ng, J. K. and Malotka, J. and Kawakami, N. and Derfuss, T. and Khademi, M. and Olsson, T. and Linington, C. and Odaka, M. and Tackenberg, B. and Pruss, H. and Schwab, J. M. and Harms, L. and Harms, H. and Sommer, C. and Rasband, M. N. and Eshed-Eisenbach, Y. and Peles, E. and Hohlfeld, R. and Yuki, N. and Dornmair, K. and Meinl, E.. (2012) Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology, Vol. 79, H. 23. pp. 2241-2248.

Derfuss, T.. (2012) Personalized medicine in multiple sclerosis: hope or reality? BMC medicine, Vol. 10 , 116.

2011

Probstel, A. K. and Dornmair, K. and Bittner, R. and Sperl, P. and Jenne, D. and Magalhaes, S. and Villalobos, A. and Breithaupt, C. and Weissert, R. and Jacob, U. and Krumbholz, M. and Kuempfel, T. and Blaschek, A. and Stark, W. and Gartner, J. and Pohl, D. and Rostasy, K. and Weber, F. and Forne, I. and Khademi, M. and Olsson, T. and Brilot, F. and Tantsis, E. and Dale, R. C. and Wekerle, H. and Hohlfeld, R. and Banwell, B. and Bar-Or, A. and Meinl, E. and Derfuss, T.. (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology, 77 (6). pp. 580-588.